Citation Impact
59 standout
Citing Papers
Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Derek-Zhen Xu being referenced
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
2020
IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
2018
Author Peers
| Author | Hepatology | PRM | Oncology | PFM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Derek-Zhen Xu | 118 | 26 | 88 | 45 | 6 | 162 | |
| Özberk Öztürk | 2 | 9 | 293 | ||||
| I. Goldfarb | 12 | 69 | 1.5k | ||||
| Margaret A. Vogel | 3 | 7 | 370 | ||||
| С. А. Хромова | 20 | 1.3k | |||||
| Evelyn Grace de Jesus | 1 | 2 | 13 | 794 |
All Works
Loading papers...